Addition of elotuzumab to standard therapy in transplant-eligible patients with MM did not improve PFS or OS in the long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback